ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2036

Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon

Andres Martinez1, Julieta Morbiducci1, Constanza Arguissain1, Maria Tamborenea1, Marisel Bejarano2, Lucia Castorino1 and Anastasia Secco1, 1Rivadavia Hospital, Buenos Aires, Argentina, 2Rivadavia´s Hospital, Buenos Aires, Argentina

Meeting: ACR Convergence 2022

Keywords: Raynaud's phenomenon, Scleroderma, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease, and Raynaud’s Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome. Hence, the importance of identifying systemic sclerosis (SSc) in its early stages. The aim of this study was to describe the occurrence of RP in a cohort of patients with pSS. To estimate the frequency of Very Early SSc, and to describe its clinical and immunological features. To determine the frequency of development of SSc (2013 classification criteria for systemic sclerosis ACR/EULAR) in patients with pSS and RP.

Methods: An observational, descriptive, retrospective cohort study was carried out. Patients with pSS, according to ACR/EULAR classification criteria 2002 and/or 2016, attending to a public hospital in Argentina, were included. Patients with SSc-overlap syndrome were excluded. In order to identify Very Early SSc, we looked for RP associated with SSc marker autoantibodies and/or sclerodermiform pattern (SDP) in capillaroscopy. Continuous variables were described as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables were expressed as percentages.

Results: Two hundred and seven patients with pSS were included. The mean age in years was 58 (± 14). The mean follow-up time in months was 111 (± 63), and 15% (n:32) of the patients with pSS had RP. The median time of RP evolution was 113 months (IQR: 45-168). Regarding capillaroscopy in patients with pSS and RP, 32% (n:8) had non-specific findings, 32% (n:8) early SDP, 24% (n:6) active SDP, and 4% (n:1) late SDP; 56% (n:18) of the patients with pSS and RP met the criteria for Very Early SSc with a median follow-up time of 55 months (IQR: 30-73); 53% (n:9) had only SDP, 12% (n:2) had SDP with specific antibodies, and 35% (n:6) had only specific antibodies. Anti-centromere antibody (ACA) predominated in 83% (n:5) and the anti Pm-Scl in 17% (n:1). Of all the patients with pSS and RP, 16% (n:5) developed SSc after a median follow-up of 62 months (IQR: 24-63).

Conclusion: The frequency of RP among our patients with pSS is similar to the one described in various series. Over half of them met the criteria for Very Early SSc. Abnormal capillaroscopy is the most frequently observed criterion. Of these patients, 16% developed SSc. ACA’s were the predominant antibodies. Consequently, it is of the utmost importance to contemplate RP in patients with pSS since Very Early SSc may have critical prognostic and therapeutic implications. Finally, the significance of capillaroscopy in the assessment of these patients is worth highlighting.


Disclosures: A. Martinez, None; J. Morbiducci, None; C. Arguissain, None; M. Tamborenea, None; M. Bejarano, None; L. Castorino, None; A. Secco, None.

To cite this abstract in AMA style:

Martinez A, Morbiducci J, Arguissain C, Tamborenea M, Bejarano M, Castorino L, Secco A. Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-of-systemic-sclerosis-in-patients-with-primary-sjogren-syndrome-and-raynauds-phenomenon/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-systemic-sclerosis-in-patients-with-primary-sjogren-syndrome-and-raynauds-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology